Adult-onset painful axonal polyneuropathy caused by a dominant<i>NAGLU</i>mutation

Martine Tétreault, Michael Gonzalez, Marie-Josée Dicaire, Pierre Allard, Kalle Gehring, Diane LeBlanc, Nadine Leclerc, Ronald Schondorf, Jean Mathieu, Stephan Züchner,

Brain · 2015 · 31 citations · 13 references

DOIFull text

Open access

Concepts

Abstract

Late-onset painful sensory neuropathies are usually acquired conditions associated with common diseases. Adult presentations of known hereditary forms are often accompanied by other organ involvement. We recruited a large French-Canadian family with a dominantly inherited late-onset painful sensory neuropathy. The main clinical feature is recurrent leg pain that progresses to constant painful paraesthesias in the feet and later the hands. As it evolves, some patients develop a mild sensory ataxia. We selected four affected individuals for whole exome sequencing. Analysis of rare variants shared by all cases led to a list of four candidate variants. Segregation analysis in all 45 recruited individuals has shown that only the p.Ile403Thr variant in the α-N-acetyl-glucosaminidase (NAGLU) gene segregates with the disease. Recessive NAGLU mutations cause the severe childhood lysosomal disease mucopolysacharidosis IIIB. Family members carrying the mutation showed a significant decrease of the enzymatic function (average 45%). The late-onset and variable severity of the symptoms may have precluded the description of such symptoms in parents of mucopolysaccharidosis IIIB cases. The identification of a dominant phenotype associated with a NAGLU mutation supports that some carriers of lysosomal enzyme mutations may develop later in life much milder phenotypes. Recessive mutations in NAGLU, which encodes α–N-acetylglucosaminidase, cause the severe childhood lysosomal disease mucopolysaccharidosis IIIB. Using whole-exome sequencing of four individuals, Tétreault et al. show that a NAGLU variant also segregates with a dominant late-onset painful sensory neuropathy, with affected individuals showing reduced α–N-acetylglucosaminidase activity.

References

13